C167H266N20O13S2 — CID 161345774
1-[(3-tert-butyl-5-methoxyphenyl)methyl]-4-methylpiperazine;4-tert-butyl-6-(oxetan-3-ylmethyl)pyrimidine;3-(3-tert-butylphenoxy)-1-methylsulfonylpyrrolidine;1-[1-(3-tert-butylphenyl)ethyl]-4-methylpiperazine;1-[(4-tert-butylphenyl)methyl]-4-methylpiperazine;4-[4-[(3-tert-butylphenyl)methyl]piperazin-1-yl]butanamide;4-[4-[(3-tert-butylphenyl)methyl]piperazin-1-yl]butanoic acid;N-[2-[4-[(3-tert-butylphenyl)methyl]piperazin-1-yl]ethyl]acetamide;4-(3-tert-butylphenyl)-1,4-thiazinane 1,1-dioxide;ethyl 2-[4-[(3-tert-butylphenyl)methyl]piperazin-1-yl]acetate (PubChem CID 161345774) has the molecular formula C167H266N20O13S2 and a molecular weight of 2826.23 g/mol. Its IUPAC name is 1-[(3-tert-butyl-5-methoxyphenyl)methyl]-4-methylpiperazine;4-tert-butyl-6-(oxetan-3-ylmethyl)pyrimidine;3-(3-tert-butylphenoxy)-1-methylsulfonylpyrrolidine;1-[1-(3-tert-butylphenyl)ethyl]-4-methylpiperazine;1-[(4-tert-butylphenyl)methyl]-4-methylpiperazine;4-[4-[(3-tert-butylphenyl)methyl]piperazin-1-yl]butanamide;4-[4-[(3-tert-butylphenyl)methyl]piperazin-1-yl]butanoic acid;N-[2-[4-[(3-tert-butylphenyl)methyl]piperazin-1-yl]ethyl]acetamide;4-(3-tert-butylphenyl)-1,4-thiazinane 1,1-dioxide;ethyl 2-[4-[(3-tert-butylphenyl)methyl]piperazin-1-yl]acetate.
| Compound Name | 1-[(3-tert-butyl-5-methoxyphenyl)methyl]-4-methylpiperazine;4-tert-butyl-6-(oxetan-3-ylmethyl)pyrimidine;3-(3-tert-butylphenoxy)-1-methylsulfonylpyrrolidine;1-[1-(3-tert-butylphenyl)ethyl]-4-methylpiperazine;1-[(4-tert-butylphenyl)methyl]-4-methylpiperazine;4-[4-[(3-tert-butylphenyl)methyl]piperazin-1-yl]butanamide;4-[4-[(3-tert-butylphenyl)methyl]piperazin-1-yl]butanoic acid;N-[2-[4-[(3-tert-butylphenyl)methyl]piperazin-1-yl]ethyl]acetamide;4-(3-tert-butylphenyl)-1,4-thiazinane 1,1-dioxide;ethyl 2-[4-[(3-tert-butylphenyl)methyl]piperazin-1-yl]acetate |
|---|---|
| PubChem CID | 161345774 |
| Molecular Formula | C167H266N20O13S2 |
| Molecular Weight | 2826.23 g/mol |
| Exact Mass | 2824.02 |
| IUPAC Name | 1-[(3-tert-butyl-5-methoxyphenyl)methyl]-4-methylpiperazine;4-tert-butyl-6-(oxetan-3-ylmethyl)pyrimidine;3-(3-tert-butylphenoxy)-1-methylsulfonylpyrrolidine;1-[1-(3-tert-butylphenyl)ethyl]-4-methylpiperazine;1-[(4-tert-butylphenyl)methyl]-4-methylpiperazine;4-[4-[(3-tert-butylphenyl)methyl]piperazin-1-yl]butanamide;4-[4-[(3-tert-butylphenyl)methyl]piperazin-1-yl]butanoic acid;N-[2-[4-[(3-tert-butylphenyl)methyl]piperazin-1-yl]ethyl]acetamide;4-(3-tert-butylphenyl)-1,4-thiazinane 1,1-dioxide;ethyl 2-[4-[(3-tert-butylphenyl)methyl]piperazin-1-yl]acetate |
| SMILES | CC(=O)NCCN1CCN(Cc2cccc(C(C)(C)C)c2)CC1.CC(C)(C)c1cc(CC2COC2)ncn1.CC(C)(C)c1cccc(CN2CCN(CCCC(=O)O)CC2)c1.CC(C)(C)c1cccc(CN2CCN(CCCC(N)=O)CC2)c1.CC(C)(C)c1cccc(N2CCS(=O)(=O)CC2)c1.CC(C)(C)c1cccc(OC2CCN(S(C)(=O)=O)C2)c1.CC(c1cccc(C(C)(C)C)c1)N1CCN(C)CC1.CCOC(=O)CN1CCN(Cc2cccc(C(C)(C)C)c2)CC1.CN1CCN(Cc2ccc(C(C)(C)C)cc2)CC1.COc1cc(CN2CCN(C)CC2)cc(C(C)(C)C)c1 |
| InChI | InChI=1S/2C19H31N3O.2C19H30N2O2.C17H28N2O.C17H28N2.C16H26N2.C15H23NO3S.C14H21NO2S.C12H18N2O/c1-16(23)20-8-9-21-10-12-22(13-11-21)15-17-6-5-7-18(14-17)19(2,3)4;1-19(2,3)17-7-4-6-16(14-17)15-22-12-10-21(11-13-22)9-5-8-18(20)23;1-19(2,3)17-7-4-6-16(14-17)15-21-12-10-20(11-13-21)9-5-8-18(22)23;1-5-23-18(22)15-21-11-9-20(10-12-21)14-16-7-6-8-17(13-16)19(2,3)4;1-17(2,3)15-10-14(11-16(12-15)20-5)13-19-8-6-18(4)7-9-19;1-14(19-11-9-18(5)10-12-19)15-7-6-8-16(13-15)17(2,3)4;1-16(2,3)15-7-5-14(6-8-15)13-18-11-9-17(4)10-12-18;1-15(2,3)12-6-5-7-13(10-12)19-14-8-9-16(11-14)20(4,17)18;1-14(2,3)12-5-4-6-13(11-12)15-7-9-18(16,17)10-8-15;1-12(2,3)11-5-10(13-8-14-11)4-9-6-15-7-9/h5-7,14H,8-13,15H2,1-4H3,(H,20,23);4,6-7,14H,5,8-13,15H2,1-3H3,(H2,20,23);4,6-7,14H,5,8-13,15H2,1-3H3,(H,22,23);6-8,13H,5,9-12,14-15H2,1-4H3;10-12H,6-9,13H2,1-5H3;6-8,13-14H,9-12H2,1-5H3;5-8H,9-13H2,1-4H3;5-7,10,14H,8-9,11H2,1-4H3;4-6,11H,7-10H2,1-3H3;5,8-9H,4,6-7H2,1-3H3 |
| InChIKey | VNGQBGJUPQULHM-UHFFFAOYSA-N |
| XLogP | 25.58 |
| TPSA | 309.38 Ų |
| H-Bond Donors | 3 |
| H-Bond Acceptors | 29 |
| Rotatable Bonds | 35 |
| Heavy Atoms | 202 |
| Complexity | — |
3 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 2826.23 |
| LogP ≤ 5 | 25.58 |
| H-Bond Donors ≤ 5 | 3 |
| H-Bond Acceptors ≤ 10 | 29 |